Fusion Pharmaceuticals

pivot change turnaround direction walk away
Biotech

AstraZeneca CEO defends 'fantastic' Alexion buy as halts drug

AstraZeneca ended development of vemircopan, triggering a $753 million charge as the drugmaker reevaluated the worth of its Alexion acquisition.
woman in snow

AstraZeneca invests $570M to grow in Canada, adds 700 jobs

Jan 23, 2025 2:47pm
Photo of a final puzzle piece about to fit into a puzzle

Top 10 smartest deals in biopharma

Jun 24, 2024 6:00am
A graphic symbolizing one group acquiring another

AstraZeneca melds with Fusion in $2B radiopharma buyout

Mar 19, 2024 5:52am
reshuffle pipeline target reorganize shift change

Fusion, Cyteir refocus pipelines to funnel cash toward best bets

May 11, 2023 11:04am